Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337. Epub 2018 Jul 25.

2.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2018 Nov 20. doi: 10.1093/ije/dyy230. [Epub ahead of print]

PMID:
30462234
3.

iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia.

Li L, Roh JH, Chang EH, Lee Y, Lee S, Kim M, Koh W, Chang JW, Kim HJ, Nakanishi M, Barker RA, Na DL, Song J.

Exp Neurobiol. 2018 Oct;27(5):350-364. doi: 10.5607/en.2018.27.5.350. Epub 2018 Oct 31.

4.

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.

Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C.

Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.

5.

Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease.

Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupré N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F.

Neurobiol Dis. 2018 Nov 5;124:163-175. doi: 10.1016/j.nbd.2018.11.002. [Epub ahead of print]

PMID:
30408591
6.

Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis.

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Oct 16;9:870. doi: 10.3389/fneur.2018.00870. eCollection 2018.

7.

Ensuring safety in public playgrounds is everybody's business.

Barker RA, Eager D, Sharwood LN.

Med J Aust. 2018 Oct 29. [Epub ahead of print] No abstract available.

PMID:
30359559
8.

Emerging Treatment Approaches for Parkinson's Disease.

Stoker TB, Torsney KM, Barker RA.

Front Neurosci. 2018 Oct 8;12:693. doi: 10.3389/fnins.2018.00693. eCollection 2018. Review.

9.

Outcome of cell suspension allografts in a patient with Huntington's disease.

Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, Barker RA, Cicchetti F.

Ann Neurol. 2018 Oct 4. doi: 10.1002/ana.25354. [Epub ahead of print]

PMID:
30286516
10.

Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease.

Gravell R, Duncan GW, Khoo TK, Burn DJ, Sayer AA, Barker RA, Lawson RA, Yarnall AJ.

J Parkinsons Dis. 2018;8(4):511-515. doi: 10.3233/JPD-181428.

PMID:
30248064
11.

Platelet-derived extracellular vesicles in Huntington's disease.

Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Weiss A, Chouinard S, Barker RA, Boilard E, Cicchetti F.

J Neurol. 2018 Sep 12. doi: 10.1007/s00415-018-9022-5. [Epub ahead of print]

PMID:
30209650
12.

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.

Palfi S, Gurruchaga JM, Lepetit H, Howard K, Ralph GS, Mason S, Gouello G, Domenech P, Buttery PC, Hantraye P, Tuckwell NJ, Barker RA, Mitrophanous KA.

Hum Gene Ther Clin Dev. 2018 Sep;29(3):148-155. doi: 10.1089/humc.2018.081.

13.

Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation.

Pircs K, Petri R, Madsen S, Brattås PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Brückner M, Lundh SH, Petersén Å, Déglon N, Hébert SS, Parmar M, Barker RA, Jakobsson J.

Cell Rep. 2018 Aug 7;24(6):1397-1406. doi: 10.1016/j.celrep.2018.07.017.

14.

The clinical heterogeneity of Parkinson's disease and its therapeutic implications.

Greenland JC, Williams-Gray CH, Barker RA.

Eur J Neurosci. 2018 Jul 30. doi: 10.1111/ejn.14094. [Epub ahead of print]

PMID:
30059179
15.

Categorising Visual Hallucinations in Early Parkinson's Disease.

Clegg BJ, Duncan GW, Khoo TK, Barker RA, Burn DJ, Yarnall AJ, Lawson RA.

J Parkinsons Dis. 2018;8(3):447-453. doi: 10.3233/JPD-181338.

PMID:
30040741
16.

Regenerative Therapies for Parkinson's Disease: An Update.

Stoker TB, Barker RA.

BioDrugs. 2018 Aug;32(4):357-366. doi: 10.1007/s40259-018-0294-1. Review.

PMID:
30027398
17.

The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.

Collins LM, Williams-Gray CH, Morris E, Deegan P, Cox TM, Barker RA.

J Neurol. 2018 Aug;265(8):1789-1794. doi: 10.1007/s00415-018-8908-6. Epub 2018 May 29.

18.

Abnormalities of age-related T cell senescence in Parkinson's disease.

Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL.

J Neuroinflammation. 2018 May 28;15(1):166. doi: 10.1186/s12974-018-1206-5.

19.

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2018 May 24;8(1):8266. doi: 10.1038/s41598-018-23083-1.

20.

New approaches for brain repair-from rescue to reprogramming.

Barker RA, Götz M, Parmar M.

Nature. 2018 May;557(7705):329-334. doi: 10.1038/s41586-018-0087-1. Epub 2018 May 16. Review.

PMID:
29769670
21.

The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G.

Stem Cell Reports. 2018 May 8;10(5):1429-1431. doi: 10.1016/j.stemcr.2018.04.010. Review.

22.

Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study.

Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT.

J Neurol. 2018 Jul;265(7):1528-1539. doi: 10.1007/s00415-018-8873-0. Epub 2018 Apr 25.

PMID:
29696499
23.

Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development.

Castiglioni V, Faedo A, Onorati M, Bocchi VD, Li Z, Iennaco R, Vuono R, Bulfamante GP, Muzio L, Martino G, Sestan N, Barker RA, Cattaneo E.

Cereb Cortex. 2018 Apr 24. doi: 10.1093/cercor/bhy092. [Epub ahead of print]

PMID:
29688344
24.

Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations.

Collins LM, Drouin-Ouellet J, Kuan WL, Cox T, Barker RA.

Version 2. F1000Res. 2017 Sep 26 [revised 2018 Jan 1];6:1751. doi: 10.12688/f1000research.12090.2. eCollection 2017.

25.

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts.

Shrigley S, Pircs K, Barker RA, Parmar M, Drouin-Ouellet J.

J Vis Exp. 2018 Feb 5;(132). doi: 10.3791/56904.

26.

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker.

Mason SL, Daws RE, Soreq E, Johnson EB, Scahill RI, Tabrizi SJ, Barker RA, Hampshire A.

Ann Neurol. 2018 Mar;83(3):532-543. doi: 10.1002/ana.25171. Epub 2018 Mar 13.

27.

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.

28.

Using Medical Claims Analyses to Understand Interventions for Parkinson Patients.

Bloem BR, Ypinga JHL, Willis A, Canning CG, Barker RA, Munneke M, De Vries NM.

J Parkinsons Dis. 2018;8(1):45-58. doi: 10.3233/JPD-171277.

29.

Erratum: Author Correction: Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.

Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, James B, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A.

NPJ Parkinsons Dis. 2017 Nov 13;3:32. doi: 10.1038/s41531-017-0034-0. eCollection 2017.

30.

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Barker RA, Parmar M, Studer L, Takahashi J.

Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

31.

11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P.

Mov Disord. 2018 Jan;33(1):117-127. doi: 10.1002/mds.27183. Epub 2017 Oct 30.

32.

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease.

Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA.

J Neurol. 2017 Dec;264(12):2457-2463. doi: 10.1007/s00415-017-8647-0. Epub 2017 Oct 26.

33.

Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study.

Wijeyekoon R, Suriyakumara V, Gamage R, Fernando T, Jayasuriya A, Amarasinghe D, Gunasekara H, Sirisena D, Amaratunga D, Muthukuda C, Barker RA, Williams-Gray C, De Silva R.

Int Arch Med. 2017 Sep 15;10. pii: 246. doi: 10.3823/2516.

34.

Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?

Drouin-Ouellet J, Pircs K, Barker RA, Jakobsson J, Parmar M.

Front Neurosci. 2017 Sep 28;11:530. doi: 10.3389/fnins.2017.00530. eCollection 2017. Review.

35.

Spatial structure normalises working memory performance in Parkinson's disease.

Fallon SJ, Bor D, Hampshire A, Barker RA, Owen AM.

Cortex. 2017 Nov;96:73-82. doi: 10.1016/j.cortex.2017.08.023. Epub 2017 Sep 1.

PMID:
28985531
36.

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2017 Jul 13;7(1):5280. doi: 10.1038/s41598-017-05709-y. Erratum in: Sci Rep. 2018 May 24;8(1):8266.

37.

Parkinson disease: Defining PD subtypes - a step toward personalized management?

Williams-Gray CH, Barker RA.

Nat Rev Neurol. 2017 Aug;13(8):454-455. doi: 10.1038/nrneurol.2017.98. Epub 2017 Jul 7. No abstract available.

PMID:
28685759
38.

Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits.

Gruszka A, Hampshire A, Barker RA, Owen AM.

Cortex. 2017 Aug;93:178-192. doi: 10.1016/j.cortex.2017.05.020. Epub 2017 Jun 3.

39.

Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.

Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, Ben James, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A.

NPJ Parkinsons Dis. 2017 Jan 9;3:2. doi: 10.1038/s41531-016-0003-z. eCollection 2017. Erratum in: NPJ Parkinsons Dis. 2017 Nov 13;3:32.

40.

REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways.

Drouin-Ouellet J, Lau S, Brattås PL, Rylander Ottosson D, Pircs K, Grassi DA, Collins LM, Vuono R, Andersson Sjöland A, Westergren-Thorsson G, Graff C, Minthon L, Toresson H, Barker RA, Jakobsson J, Parmar M.

EMBO Mol Med. 2017 Aug;9(8):1117-1131. doi: 10.15252/emmm.201607471.

41.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

42.

Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD).

Kirkeby A, Parmar M, Barker RA.

Prog Brain Res. 2017;230:165-190. doi: 10.1016/bs.pbr.2016.11.011. Epub 2017 Feb 7.

PMID:
28552228
43.

Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis.

Garofalo S, Justicia A, Arrondo G, Ermakova AO, Ramachandra P, Tudor-Sfetea C, Robbins TW, Barker RA, Fletcher PC, Murray GK.

Front Neurol. 2017 Apr 24;8:156. doi: 10.3389/fneur.2017.00156. eCollection 2017.

44.

Neural grafting for Parkinson's disease: challenges and prospects.

Stoker TB, Blair NF, Barker RA.

Neural Regen Res. 2017 Mar;12(3):389-392. doi: 10.4103/1673-5374.202935. Review.

45.

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.

Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2017 Jul;40:40-46. doi: 10.1016/j.parkreldis.2017.04.006. Epub 2017 Apr 12.

46.

Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.

Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Mollenhauer B, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O'Brien JT.

Neurobiol Aging. 2017 Jul;55:78-90. doi: 10.1016/j.neurobiolaging.2017.03.012. Epub 2017 Mar 16.

47.

A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.

Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH.

Sci Rep. 2017 Mar 21;7:44899. doi: 10.1038/srep44899.

48.

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.

Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, O'Brien JT, Barker RA, Maxwell RJ, Brooks DJ, Burn DJ.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):310-316. doi: 10.1136/jnnp-2016-313918. Epub 2016 Oct 6.

49.

Formation of hippocampal mHTT aggregates leads to impaired spatial memory, hippocampal activation and adult neurogenesis.

Schwab LC, Richetin K, Barker RA, Déglon N.

Neurobiol Dis. 2017 Jun;102:105-112. doi: 10.1016/j.nbd.2017.03.005. Epub 2017 Mar 9.

PMID:
28286179
50.

Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.

Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Burn DJ; ICICLE-PD study group.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):648-652. doi: 10.1136/jnnp-2016-315099. Epub 2017 Mar 1.

Supplemental Content

Loading ...
Support Center